Consortium of Multiple Sclerosis Centers Annual Meeting (CMSC)

Neurologists Sarah Simmons, MD, PhD, and Fatma Inanici, MD, PhD, discuss how the combination of noninvasive cervical spinal cord stimulation with exercise therapy can improve upper extremity function in people with MS.

The senior vice president for research at the Kessler Foundation discussed findings showing associations between reductions in neurofilament light chain and gains in cognitive processing speed, verbal memory, and visual memory in patients with early relapsing multiple sclerosis treated with ozanimod. [WATCH TIME: 3 minutes]

The new president of Consortium of Multiple Sclerosis Centers (CMSC) discussed key themes in multiple sclerosis care presented at the 2026 CMSC Annual Meeting. [WATCH TIME: 11 minutes]

The professor of neurology at the University of Colorado discussed evidence from DISCOMS and other trials on disease-modifying therapy discontinuation in older, stable patients with multiple sclerosis. [WATCH TIME: 8 minutes]

At CMSC 2026, the neuroimmunologist and director at OhioHealth MS Center, discussed results from the phase 3 FENhance 1 and 2 studies, highlighting significant reductions in relapse rates and robust MRI outcomes. [WATCH TIME: 3 minutes]

The neurologist at Orlando Health discussed findings from an analysis of cladribine tablets in patients aged 50 years and older with relapsing multiple sclerosis presented at CMSC 2026. [WATCH TIME: 7 minutes]

The research neuropsychologist at Mount Sinai Rehabilitation Hospital outlined hallmark patterns of cognitive impairment in multiple sclerosis at the 2026 CMSC Annual Meeting. [WATCH TIME: 6 minutes]

The assistant professor of neurology at NYU Grossman School of Medicine discussed how optical coherence tomography can support the 2024 McDonald Criteria for multiple sclerosis at CMSC 2026.

A clinical research coordinator at SunnyBrook Health Sciences Centre, explained key factors of the computerized cognitive training program that contributed to cognitive improvement. [WATCH TIME: 3 minutes]

The neurologist at St. Michael's Hospital shared findings presented at CMSC 2026 from a large dataset on preconception ocrelizumab exposure among women with multiple sclerosis. [WATCH TIME: 5 minutes]

Kyle Blackburn, MD, a neurologist at UT Southwestern Medical Center, discussed new proposed updates to the diagnostic criteria and nosology for myelitis presented at the 2026 CMSC Annual Meeting.

CMSC 2026 registry data showed low relapse rates and no new safety signals among adults with AQP4-positive NMOSD treated with eculizumab or ravulizumab in real-world practice.

At CMSC 2026, Jamie Lynn Sigler, an actress and patient advocate, shared her perspective on living with multiple sclerosis, emphasizing informed decision-making and treatment consistency. [WATCH TIME: 7 minutes]

The director of the Stony Broke MS Comprehensive Care Center reviewed late-breaking subgroup data evaluating high-efficacy therapy in patients with highly active relapsing multiple sclerosis and discussed the evolving role of early intervention. [WATCH TIME: 5 minutes]

New data presented at CMSC 2026 suggest ocrelizumab provides comparable relapse and MRI control in pediatric- and young-adult–onset multiple sclerosis, with greater disability improvement observed in pediatric patients.

German 3-year real-world data shows ozanimod keeps RRMS relapses low, disability stable, and safety consistent in routine care.

A retrospective study presented at CMSC 2026 found GLP-1 receptor agonist use in multiple sclerosis was associated with higher physical activity levels and improvements across several patient-reported symptom domains.

Three-year extension data presented at CMSC 2026 showed sustained suppression of MRI activity and low relapse rates with frexalimab in relapsing multiple sclerosis.

A new analysis presented at CMSC 2026 suggests that rescue treatment with complement inhibition may help stabilize disease activity in Hispanic patients with NMOSD who experienced relapse despite treatment.

A real-world study presented at CMSC 2026 reported year-1 improvements in treatment satisfaction and disease impact measures in patients with MS treated with ublituximab.

An analysis from the phase 3b ENLIGHTEN study presented at the 2026 CMSC Annual Meeting showed that cognitive performance remained stable during long-term treatment with ozanimod in patients with relapsing multiple sclerosis.

Kathleen Costello, CRNP, MSCN, offers highlights of the upcoming 2026 CMSC Annual Meeting, which will celebrate 40 years of progress and innovation in MS care.

At CMSC 2025, assistant professor of neurology at the University of California, San Francisco discussed progress on the integration of biomarkers into clinical practice for multiple sclerosis. [WATCH TIME: 4 minutes]

A new study reveals higher rates of postpartum depression in women with multiple sclerosis, emphasizing the need for early screening and management strategies.

A recent analysis highlights the increasing use of Octave's MSDA test in managing multiple sclerosis, showcasing its impact on treatment decisions and disease monitoring.

Gabrielle Macaron, MD, assistant professor of neuroscience at Université de Montréal, discussed the nuanced clinical decision-making involved in initiating a DMT for patients newly diagnosed with MS.

At CMSC 2025, Cassandra Moore, MPH, CPH, associate vice president of strategy and innovation at the National MS Society, discussed the impact of health and wellness coaching in patients with multiple sclerosis.

The assistant professor in the Department of Neuroscience at Université de Montréal discussed the importance of weighing the risks of multiple sclerosis against treatment risks, emphasizing individualized care. [WATCH TIME: 4 minutes]

The associate vice president of strategy and innovation at the National MS Society highlighted the measurable benefits of health and wellness coaching for individuals with multiple sclerosis. [WATCH TIME: 5 minutes]

The director of the John A. Schafer, MD Multiple Sclerosis Achievement Center at Dignity Health discussed the effect of loneliness and social isolation on individuals living with multiple sclerosis.